Our Technology

Trillium Therapeutics is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. Our SIRPαFc and CD200 monoclonal antibody programs, target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. 

Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical programs are an orally-available bromodomain inhibitor, and an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

Thumb Download


Email Address: *
First Name:
Mailing Lists

Enter the code shown above.

Powered By Q4 Inc.